Subscribe
shutterstock_1144555808_piotr_swat
Piotr Swat / Shutterstock.com
10 October 2019AsiaRory O'Neill

Insilico Medicine signs $200m AI drug discovery deal

Hong Kong-based Insilico Medicine has agreed an artificial intelligence (AI) breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

More on this story

Big Pharma
EU invests €35m into AI cancer diagnostics
10 July 2019   The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Big Pharma
Novartis and BenevolentAI sign AI oncology deal
9 September 2019   Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug